HOME >> BIOLOGY >> NEWS
Macrochem acquires option to license pexiganan

WELLESLEY HILLS, Mass., July 10 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTCBB: MACM - News) today announced that it has signed an exclusive option to acquire exclusive worldwide license rights for drug uses of pexiganan, a novel, small peptide anti-infective for topical treatment of patients with mild diabetic foot infection (DFI), from Genaera Corporation (Genaera).

"We believe this is a unique opportunity for MacroChem to broaden its product portfolio with a product that has already completed two Phase 3 clinical trials. It also fits our strategic focus and complements our lead product candidate, EcoNail(TM) for treatment of nail fungus currently in a fully enrolled Phase 2 trial and progressing on track with an interim assessment of clinical data later this year after all patients have been treated for twenty four weeks," said Robert J. DeLuccia, President and CEO of MacroChem.

Clinical trials with pexiganan previously conducted by Genaera include two Phase 3 trials submitted in a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in 1998. At that time, outstanding issues with CMC (Chemistry, Manufacturing and Controls) and an FDA request for one additional controlled trial precluded approval.

Mr. DeLuccia further noted, "We would be pleased to have pexiganan in our hands since we believe that, if approved, it would be welcomed by physicians and patients for the treatment of diabetic foot infection. In recent years, there have been many advances in the manufacturing of peptides, a better understanding of the treatment of diabetic foot infection, improvements in clinical trial design and execution, and more clarity concerning regulatory requirements for topical anti-infectives with the potential market being even more attractive than before."

He added, "There continues to be a very large and growing incidence of diabetes and, as a result, a growing number of diabetic foot infections in the
'"/>

Contact: Bill Douglass
bdouglass@investorrelationsgroup.com
212-825-3210
MacroChem
10-Jul-2007


Page: 1 2

Related biology news :

1. Biogen Idec acquires Brandeis spin-out
2. Wiley acquires publications from Carpe Diem Communications
3. Ossur hf. acquires the Gibaud Group in France
4. Springer acquires BioTribune Magazine and Biotribune.com
5. Stevens Davidson Laboratory acquires new research vessel
6. Accentia Biopharmaceuticals acquires exclusive license
7. Ossur acquires US orthotics company Royce Medical
8. Molecular Profiling Institute, Inc. acquires NanoBiomics, Inc.
9. European approval of HIV drug darunavir will provide a potent new option with Fuzeon
10. Fat stem cells being studied as option for breast reconstruction
11. Drug offers new options for leukemia patients

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Macrochem acquires option license pexiganan

(Date:10/14/2014)... – October 14, 2014 – Scientists from The Scripps ... the National Institutes of Health (NIH) to lead an ... hemorrhagic fever disease in Africa. The study aims to ... some patients die, while others survive the inflection. ... the basic mechanism of how Lassa fever virus causes ...
(Date:10/14/2014)... international team of researchers, led by the Chinese Academy ... Nature Genetics a brief genomic history of ... the tomato plant. , The C.M. Rick Tomato Genetics ... in this study by providing seed of both cultivated ... which builds on the first tomato genome sequence completed ...
(Date:10/14/2014)... – Over the past decades, we have seen numerous ... the needs of infants for social contact and stimulation ... thrive. , Infancy and childhood are critical ... A generation of research suggests that enriched environments, full ... cognitive function. In contrast, deprivation and stress may compromise ...
Breaking Biology News(10 mins):Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2Institutional rearing may increase risk attention-deficit disorder 2
(Date:10/18/2014)... October 18, 2014 The Asian arthroscopic ... Asia with analysis and forecast of revenue. The arthroscopic ... $712.3 million by 2018, at a CAGR of 6.5% ... of the Asian arthroscopic devices market, to get an ... a glimpse of the segmentation of arthroscopic devices market ...
(Date:10/18/2014)... NY (PRWEB) October 18, 2014 The ... healthy rate in the five years to 2014. The ... federal renewable energy tax credits that encouraged the use ... enacted renewable portfolio standards (RPSs), which require local utilities ... of their total energy portfolio. Increased campaigning for green ...
(Date:10/17/2014)... engineering professors have received a $451,781 Air Force Office ... at the micro- and nano-scale level that will provide ... professor of Mechanical and Aerospace Engineering, said the new ... than taking X-rays of an aircraft,s wing., "We,ll be ... when we look at it on this scale," Huang ...
(Date:10/17/2014)... October 17, 2014 Bioquell, provider ... upon by health facilities around the world to ... being treated. Among the many places the hydrogen ... Health Presbyterian Hospital Dallas and at the National ... vapor-producing robots have been utilized to decontaminate patient ...
Breaking Biology Technology:The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 2The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 3The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 4Biomass Power in the US Industry Market Research Report from IBISWorld Has Been Updated 2Biomass Power in the US Industry Market Research Report from IBISWorld Has Been Updated 3UT Arlington project to detect possible damages in aircraft parts early in process 2Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 2Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 3Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 4Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 5Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 6
Cached News: